GlassScriptPhysician profile
Aslam Syed
NPI 1487097481
$1,970.59
in general payments reported to CMS, 2019-2025
15 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $404 · 2021: $254 · 2022: $127 · 2023: $102 · 2024: $700 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.35 | 2019-2025 | Mavyret |
| Mallinckrodt Hospital Products INC. | $341.64 | 2020-2021 | |
| Janssen Biotech, INC. | $263.31 | 2019-2025 | Simponi, Stelara, Simponi Aria |
| Qol Medical, LLC | $202.12 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $121.41 | 2021-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $120.93 | 2020-2021 | |
| Genzyme Corporation | $94.65 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $88.64 | 2024-2025 | Dupixent |
| Mallinckrodt Enterprises LLC | $76.87 | 2019 | |
| Ardelyx, INC. | $29.54 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $28.50 | 2025 | Voquezna |
| Shionogi INC | $26.91 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.99 | 2024 | Bylvay |
| Apollo Endosurgery US INC | $18.49 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.24 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aslam Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.